Regulatory T-cells and effects of anti-CTLA4 and anti-PD1 therapy in a transgenic murine model of neuroblastoma

被引：0
|
作者：
Chan, Randall [1 ]
Shirinbak, Soheila [1 ]
Muthugounder, Sakunthala [1 ]
Hung, Long [1 ]
Gnanachandran, Janahan [1 ]
Hajidaniel, Michael [1 ]
Asgharzadeh, Shahab [1 ]
机构：
[1] USC Childrens Hosp Los Angeles, Los Angeles, CA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-5021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5021
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes
    Lui, David Tak Wai
    Lee, Chi Ho
    Tang, Vikki
    Fong, Carol Ho Yi
    Lee, Alan Chun Hong
    Chiu, Joanne Wing Yan
    Leung, Roland Ching Yu
    Kwok, Gerry Gin Wai
    Li, Bryan Cho Wing
    Cheung, Tan To
    Woo, Yu Cho
    Lam, Karen Siu Ling
    Yau, Thomas
    ENDOCRINE PRACTICE, 2021, 27 (09) : 886 - 893
  • [32] Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
    James D. Lord
    Robert C. Hackman
    Amanda Moklebust
    John A. Thompson
    Celestia S. Higano
    Deborah Chielens
    Gideon Steinbach
    George B. McDonald
    Digestive Diseases and Sciences, 2010, 55 : 1396 - 1405
  • [33] Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
    Lord, James D.
    Hackman, Robert C.
    Moklebust, Amanda
    Thompson, John A.
    Higano, Celestia S.
    Chielens, Deborah
    Steinbach, Gideon
    McDonald, George B.
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (05) : 1396 - 1405
  • [34] Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells
    Khan, Sameena
    Burt, Deborah J.
    Ralph, Christy
    Thistlethwaite, Fiona C.
    Hawkins, Robert E.
    Elkord, Eyad
    CLINICAL IMMUNOLOGY, 2011, 138 (01) : 85 - 96
  • [35] Antifungals improve anti-PD1 efficacy in a murine breast cancer model
    Kershaw, Kathleen
    Henson, Regina M.
    Abrajan, Brandon
    Choi, Rachel Y.
    Underhill, David M.
    Shiao, Stephen L.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [36] Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
    Simeone, Ester
    Ascierto, Paolo A.
    JOURNAL OF IMMUNOTOXICOLOGY, 2012, 9 (03) : 241 - 247
  • [37] Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
    Qiaoyun Tan
    Liyuan Dai
    Yanrong Wang
    Shuxia Liu
    Te Liang
    Rongrong Luo
    Shasha Wang
    Ning Lou
    Haizhu Chen
    Yu Zhou
    Qiaofeng Zhong
    Jianliang Yang
    Puyuan Xing
    Xingsheng Hu
    Yutao Liu
    Shengyu Zhou
    Jiarui Yao
    Di Wu
    Zhishang Zhang
    Le Tang
    Xiaobo Yu
    Xiaohong Han
    Yuankai Shi
    Cancer Immunology, Immunotherapy, 2022, 71 : 1681 - 1691
  • [38] Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
    van Hooren, Luuk
    Sandin, Linda C.
    Moskalev, Igor
    Ellmark, Peter
    Dimberg, Anna
    Black, Peter
    Totterman, Thomas H.
    Mangsbo, Sara M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 47 (02) : 385 - 393
  • [39] CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer
    Oshima, Kotoe
    Shoji, Hirokazu
    Boku, Narikazu
    Hirano, Hidekazu
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Kudo-Saito, Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (03): : 1174 - 1189
  • [40] Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
    Tan, Qiaoyun
    Dai, Liyuan
    Wang, Yanrong
    Liu, Shuxia
    Liang, Te
    Luo, Rongrong
    Wang, Shasha
    Lou, Ning
    Chen, Haizhu
    Zhou, Yu
    Zhong, Qiaofeng
    Yang, Jianliang
    Xing, Puyuan
    Hu, Xingsheng
    Liu, Yutao
    Zhou, Shengyu
    Yao, Jiarui
    Wu, Di
    Zhang, Zhishang
    Tang, Le
    Yu, Xiaobo
    Han, Xiaohong
    Shi, Yuankai
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1681 - 1691
12345